Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
Pronounced racial differences in HBsAg loss after stopping nucleos(t)ide
Key clinical point: HBsAg loss, a marker for functional cure of hepatitis B, is more common among Whites after stopping NA therapy.
Major finding: The hazard ratio for HBsAg loss for Whites vs. Asians was 5.8 (P < .001).
Study details: Retrospective cohort of 1,541 patients with hepatitis B infections.
Disclosures: The study was supported by the RETRACT-B group. Grishma Hirode and Dr. Lok reported nor relevant disclosures.
Citation:
Hirode G et al. AASLD 2020. Abstract 23.